Reduced Risk of Cardiovascular Events
"These medications do much more than help control blood sugar or weight. They significantly reduce the risk of heart attacks, strokes and premature death."
— Dr. Simon Cork, Anglia Ruskin University
A recent meta-analysis of 11 major cardiovascular outcome trials, involving over 90,000 patients, has delivered a significant finding: treatment with GLP-1 receptor agonists is associated with a lower risk of major adverse cardiovascular events—including heart attack, stroke, and cardiovascular death.
- The analysis reported an approximately 13% reduction in risk compared to a placebo over an average follow-up period of nearly three years.
- Only studies with a minimum follow-up period of one year were included.
- Observed benefits were consistent across different patient groups, including those with type 2 diabetes, obesity, or existing heart disease.
- Benefits were observed regardless of whether patients had diabetes.
- Patients taking the drugs also showed lower all-cause mortality, fewer non-fatal heart attacks and strokes, and fewer hospital admissions for heart failure.
- The results were consistent across different GLP-1 drugs (semaglutide, liraglutide, dulaglutide) and trial designs.
- No meaningful increase in serious safety concerns, such as severe hypoglycemia or acute pancreatitis, was identified. Gastrointestinal side effects (e.g., nausea, vomiting) were more common but are already well-documented.
The meta-analysis was published in the journal Cardiovascular Diabetology – Endocrinology Reports.
Potential for Improving Heart Attack Recovery
"These drugs may improve blood flow through the heart’s smallest blood vessels."
— Prof. Bryan Williams, British Heart Foundation
Separate research has investigated the potential of GLP-1 drugs to treat common post-heart attack complications. This study focused on the condition known as 'no-reflow', where tiny blood vessels in the heart remain narrowed even after emergency treatment, preventing blood from reaching certain heart tissues.
- This condition affects up to 50% of the approximately 100,000 annual heart attack patients in the UK.
- It increases the risk of mortality or hospital readmission for heart failure within one year.
Dr. Svetlana Mastitskaya, lead author of the study and a senior lecturer at Bristol University's medical school, noted that the findings suggest GLP-1 drugs may prevent this issue. The study also proposed that these drugs could potentially be administered by paramedics to heart attack patients.
Important Considerations:- The current results are derived from animal model trials.
- Further human studies are necessary to confirm these benefits before GLP-1s can be used for this purpose in people.
The trial was funded by the British Heart Foundation and included experts from University College London. The results were published in Nature Communications.